Skip to Main Content
Table 1

Patient characteristics and docetaxel exposure (n = 180)

No. (%)Median5–95% percentile
Age (years)  61 43–72 
Sex    
 Male 118 (66)   
 Female 62 (34)   
WHO performance status    
 0 35 (19)   
 1 113 (63)   
 2 32 (18)   
AAG (grams/liter)  1.42 0.84–2.71 
Time from diagnosis (month)  4.7 0.6–39 
 >12 months 48 (27)   
Extent of disease    
 Number of disease sites    
  1 48 (27)   
  2 70 (39)   
  3 42 (23)   
  ≥4 20 (11)   
 Liver metastasis 34 (19)   
Prior treatments    
 Chemotherapy 52 (29)   
 Number of prior regimen    
  0 128 (71)   
  1 34 (19)   
  ≥2 18 (10)   
 Previous platinum 43 (24)   
 Radiotherapy 70 (39)   
Docetaxel exposure    
 CL (liters/h)  35.7 17.8–58.8 
 AUC (μg·h/ml)  4.98 3.24–9.76 
No. (%)Median5–95% percentile
Age (years)  61 43–72 
Sex    
 Male 118 (66)   
 Female 62 (34)   
WHO performance status    
 0 35 (19)   
 1 113 (63)   
 2 32 (18)   
AAG (grams/liter)  1.42 0.84–2.71 
Time from diagnosis (month)  4.7 0.6–39 
 >12 months 48 (27)   
Extent of disease    
 Number of disease sites    
  1 48 (27)   
  2 70 (39)   
  3 42 (23)   
  ≥4 20 (11)   
 Liver metastasis 34 (19)   
Prior treatments    
 Chemotherapy 52 (29)   
 Number of prior regimen    
  0 128 (71)   
  1 34 (19)   
  ≥2 18 (10)   
 Previous platinum 43 (24)   
 Radiotherapy 70 (39)   
Docetaxel exposure    
 CL (liters/h)  35.7 17.8–58.8 
 AUC (μg·h/ml)  4.98 3.24–9.76 
Close Modal

or Create an Account

Close Modal
Close Modal